HomeSearchNewsCoursesEvents
GroupsRoomsMy tribePublicationsCase studies
Content StudioCreator studioAnalytics
Settings
  1. Home
  2. ›Groups
  3. ›Oncology Exchange Program
OpenOncology

Oncology Exchange Program

5 members · Oncology

Room membership is not a relationship. Following and connecting happen on people, never on rooms.

Feed3Members5About

A dedicated community for oncologists to discuss emerging evidence, challenging cases, clinical guidelines, and innovations shaping cancer care. Here you can: 📚 Share publications 💬 Discuss difficult cases 🎥 Watch expert talks 📊 Participate in polls

Join the room to post to its feed.
NJ
Niki Jain · Oncology · 1mo

Your preferred next step?

Your preferred next step?

0 votes

NJ
Niki Jain · Oncology · 1mo

Seeking Expert Opinions: Management of Early Triple-Negative Breast Cancer. The multidisciplinary team is considering neoadjuvant systemic therapy. What would be your preferred management approach? 👩 Patient Profile Age: 52 years Sex: Female ECOG Performance Status: 0 Medical History: Well-controlled hypertension Family History: Mother diagnosed with breast cancer at 58 years Clinical Presentation A 2.8 cm palpable mass was detected in the left breast during routine examination. Investigations Core biopsy: Invasive ductal carcinoma ER: Negative PR: Negative HER2: Negative (IHC 0) Ki-67: 70% MRI breast: Solitary 2.8 cm lesion No chest wall invasion Axillary ultrasound: One suspicious lymph node PET-CT: No evidence of distant metastases Clinical Stage: cT2N1M0 (Stage IIB)

de-identified-case
NJ
Niki Jain · Oncology · 1mo

Be a part of this group

About

A dedicated community for oncologists to discuss emerging evidence, challenging cases, clinical guidelines, and innovations shaping cancer care. Here you can: 📚 Share publications 💬 Discuss difficult cases 🎥 Watch expert talks 📊 Participate in polls

OpenOncology
5
Members
3
Posts
2026
Founded

Members

The member list opens when you join.

Group rules

  • Post as yourself - verified identity, real clinical experience.
  • De-identify every case. No patient-identifiable data, ever.
  • Cite sources. Guideline, trial or preprint - link it.
All rules →